Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Phone+1-609-4952200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees19
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its earnings results on Thursday, September, 12th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.26. The biopharmaceutical company had revenue of $60.27 million for the quarter. View Palatin Technologies' Earnings History.
When is Palatin Technologies' next earnings date?
What price target have analysts set for PTN?
3 brokers have issued twelve-month target prices for Palatin Technologies' shares. Their predictions range from $3.00 to $8.00. On average, they anticipate Palatin Technologies' stock price to reach $5.67 in the next year. This suggests a possible upside of 574.6% from the stock's current price. View Analyst Price Targets for Palatin Technologies.
What is the consensus analysts' recommendation for Palatin Technologies?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.
What are Wall Street analysts saying about Palatin Technologies stock?
Here are some recent quotes from research analysts about Palatin Technologies stock:
- 1. According to Zacks Investment Research, "Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. " (8/27/2019)
- 2. HC Wainwright analysts commented, "Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors." (1/11/2019)
Has Palatin Technologies been receiving favorable news coverage?
Media stories about PTN stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Palatin Technologies earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Palatin Technologies.
Are investors shorting Palatin Technologies?
Palatin Technologies saw a increase in short interest in September. As of September 30th, there was short interest totalling 24,840,000 shares, an increase of 7.7% from the August 30th total of 23,070,000 shares. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 18.0 days. Currently, 11.7% of the shares of the company are short sold. View Palatin Technologies' Current Options Chain.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Senseonics (SENS), Exagen (XGN), Renalytix Ai (RENX), Profound Medical (PRN), Oncosil Medical (OSL), BARD1 Life Sciences (BD1), Yourgene Health (YGEN), MaxCyte (MXCT), Oncimmune (ONC), Sernova (SVA), Lexagene (LXG) and SQI Diagnostics (SQD).
What other stocks do shareholders of Palatin Technologies own?
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)
- Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)
- Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)
- Burns McClellan, VP of Investor Relations
Who are Palatin Technologies' major shareholders?
Palatin Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.03%) and Summit X LLC (0.01%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.
Which institutional investors are buying Palatin Technologies stock?
PTN stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Summit X LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $0.84.
How big of a company is Palatin Technologies?
What is Palatin Technologies' official website?
How can I contact Palatin Technologies?
Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.
MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
